US NCI, BMS project evaluates digital signatures in speeding trial start dates
This article was originally published in SRA
Results of the first phase of an ongoing pilot project in the US by the National Cancer Institute Cancer Therapy Evaluation Program (CTEP) and Bristol-Myers Squibb have demonstrated that, compared with the use of paper hard copy documents, the use of digital signatures and cloud computing saved significant time and costs of initiating clinical trials, while also ensuring researcher and patient identities were protected.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.